Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate Hearings On IoM Medical Errors Report Planned For Early 2000

Executive Summary

Senate Labor/HHS Appropriations Subcommittee Chairman Specter (R-Penn.) is planning a hearing to discuss recommendations outlined in a Nov. 29 Institute of Medicine report on medical errors and patient safety.

You may also be interested in...



Risk Management Assessments Will Be Part Of Advisory Committees - FDA

Risk management and other postmarketing safety considerations should be discussed during pre-approval advisory committee meetings, CDER participants maintained in a June 22 satellite workshop on minimizing pharmaceutical contributions to medical errors.

Risk Management Assessments Will Be Part Of Advisory Committees - FDA

Risk management and other postmarketing safety considerations should be discussed during pre-approval advisory committee meetings, CDER participants maintained in a June 22 satellite workshop on minimizing pharmaceutical contributions to medical errors.

Medical Error Reduction Effort Will Be Led Initially By AHRQ (Formerly AHCPR)

The Agency for Healthcare Research & Quality has new Congressional authorization for research and demonstration projects to prevent medical errors, AHRQ Director John Eisenberg, MD, noted during a Dec. 13 Senate Appropriations/HHS Subcommittee hearing.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS035275

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel